Nakatoh, Shinichi http://orcid.org/0000-0001-7928-0014
Fujimori, Kenji
Ishii, Shigeyuki
Tamaki, Junko
Okimoto, Nobukazu
Ogawa, Sumito
Iki, Masayuki
Article History
Received: 29 September 2022
Accepted: 24 January 2023
First Online: 28 February 2023
Declarations
:
: S. Nakatoh has received payments for lectures, including speakers' bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd.; Amgen K.K.; and Astellas Pharma Inc. N. Okimoto has received consulting fees from Asahi-Kasei Pharmaceutical Co., Ltd. and Teijin Pharma Ltd. N. Okimoto has received payments for lectures, including speakers' bureau fees from Asahi-Kasei Pharmaceutical Co., Ltd.; Amgen Astellas Bio Pharma K.K.; Astellas Pharma Inc.; Chugai Pharmaceutical Co.; Daiichi-Sankyo Co., Ltd.; Eisai Co., Ltd.; Eli Lilly Japan; and Teijin Pharma Ltd. The other authors have no conflicts of interest to declare.
: The study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Kindai University Faculty of Medicine (approval number: 31–065).
: The study data were completely anonymized. All data used in our analysis were deidentified by the Ministry of Health, Labour and Welfare. This study was performed in accordance with the guidelines of the Ministry of Information Security. Thus, informed consent was not required.
: The data in this study were completely anonymous. All data used in our analysis were deidentified by the Ministry of Health, Labour and Welfare, and this study followed the guidelines of the Ministry of Information Security. Thus, informed consent was not required.